BioLife Solutions, Inc. (NASDAQ:BLFS) Q1 2026 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Q1 2026 Shareholder and Analyst Conference Call.
Biolife Solutions Inc (BLFS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Casdin Capital Eli Casdin | 5,957,165 | $113,662,708 | 8.61% | |
| 2. | Royce & Associates Chuck Royce | 584,011 | $11,142,930 | +41% | 0.11% |
| 3. | Ranger Investment Management Conrad Doenges (Cio) | 269,365 | $5,139,484 | -1% | 0.37% |
| 4. | Citadel Investment Group Ken Griffin | 244,172 | $4,658,802 | +151% | 0% |
| 5. | Renaissance Technologies Jim Simons | 207,128 | $3,952,002 | -8% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.19 | 927,165 | $10,374,976.35 | 8,557,165 | 2023-10-19 | Filing | |
| $13.20 | 58,465 | $771,743.85 | 7,630,000 | 2023-08-09 | Filing | |
| $21.86 | 24,973 | $545,789.91 | 150,000 | 2023-05-22 | Filing | |
| $22.55 | 50,000 | $1,127,430.00 | 125,027 | 2023-05-19 | Filing | |
| $21.76 | 30,000 | $652,692.00 | 75,027 | 2023-05-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $19.17 | 2,577 | $49,401.09 | 108,758 | 2026-03-23 | Filing | |
| $20.00 | 500 | $10,000.00 | 113,242 | 2026-03-09 | Filing | |
| $20.15 | 96,923 | $1,952,998.45 | 113,742 | 2026-03-05 | Filing | |
| $20.74 | 111 | $2,302.14 | 49,932 | 2026-03-03 | Filing | |
| $20.74 | 418 | $8,669.32 | 210,665 | 2026-03-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,101,765 | $116,421,676 | 0% | |
| 2. | 2,348,532 | $44,809,991 | 0.01% | |
| 3. | 1,917,708 | $36,589,869 | 0% | |
| 4. | 1,577,076 | $30,090,610 | 0% | |
| 5. | 1,470,252 | $28,052,403 | 0% |
News See All
BioLife Solutions, Inc. (NASDAQ:BLFS) Q4 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions, Inc. Q4 2025 Shareholder and Analyst Conference Call.
BioLife Solutions, Inc. (NASDAQ:BLFS) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Third Quarter 2025 Shareholder and Analyst Conference Call.
BioLife Solutions, Inc. (NASDAQ:BLFS) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Q2 2025 Shareholder and Analyst Conference Call.
H.C. Wainwright Maintains Buy rating on BioLife (BLFS) Stock
On May 27, H.C. Wainwright reaffirmed its Buy rating on BioLife Solutions, Inc. (NASDAQ:BLFS) while keeping the price target the same at $30.
BioLife Solutions, Inc. (NASDAQ:BLFS) Q1 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions First Quarter 2025 Shareholder and Analyst Conference Call.
BioLife Solutions, Inc. (NASDAQ:BLFS) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Q3 2024 Shareholder and Analyst Conference Call.
BioLife Solutions (BLFS) Surpassed Revenue and Earnings-Per-Share Expectations in Q2
Conestoga Capital Advisors, an asset management company, released its “Micro-Cap Strategy” second-quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Best Organ Transplant and Diagnosis Stocks To Buy Now
In the dynamic landscape of healthcare, the importance of organ transplantation cannot be overstated.
BioLife Solutions, Inc. (NASDAQ:BLFS) Q1 2024 Earnings Call Transcript
BioLife Solutions, Inc. beats earnings expectations. Reported EPS is $-0.19, expectations were $-0.26.